Additionally, GBM patients that survived longer than an expected 12-month period and had an unmethylated O-6-methylguanine methyltransferase (MGMT) promoter also had a significantly higher miR-181d expression in their tumor tissue (p < 0.05) (Figure 2D). The gene discussed is MGMT; the disease is glioblastoma.